No Relevant Pharmacokinetic Drug–Drug Interaction Between the Sodium-Glucose Co-Transporter-2 Inhibitor Empagliflozin and Lobeglitazone, a Peroxisome Proliferator-Activated Receptor-γ Agonist, in Healthy Subjects

PURPOSE: Combination therapy with insulin-independent sodium-glucose cotransporter 2 inhibitors and thiazolidinedione drugs, such as lobeglitazone, has been reported to elicit potential additive efficacy in glycemic control in type 2 diabetes mellitus. This study was conducted to evaluate the pharma...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Drug Des Devel Ther
Asıl Yazarlar: Kim, Yu Kyong, Hwang, Jun Gi, Park, Min Kyu
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Dove 2021
Konular:
Original Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8089085/
https://ncbi.nlm.nih.gov/pubmed/33953542
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S302215
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller